Literatur
-
1
Almer L O, Troedsson A, Arborelius M. et al .
Insulin inhalation - at least
a break-through.
Diabetes Res Clin Pract.
1988;
5
163
-
2
Banting F G, Best C H.
Pancreatic extracts.
J
Lab Clin Med.
1922;
7
467-474
-
3
Brange J, Owens D R, Kang S, Volund A.
Monomeric
insulins and their experimental and clinical implications.
Diab
Care.
1990;
13
923-954
-
4
Cefalu W T, Gelfand R A, Kourides I A.
A three month, multicenter clinical
trial of therapy with inhaled human insulin in type 2 diabetes mellitus.
Diabetologia.
1998;
41
A872
(Suppl 1)
-
5
Dapergolas G, Gregoriadis G.
Hypoglycaemic effect
of liposome-entrapped insulin administered intragastrically in rats.
Lancet.
1976;
2
824-827
-
6
Del Sindaco P, Ciofetta M, Lalli C. et al .
Use of the short-acting insulin analogue
lispro in intensive treatment of type 1 diabetes mellitus: importance
of appropriate replacement of basal insulin and time-interval injection-meal.
Diab
Med.
1998;
15
592-600
-
7 Farr S J, Gonda I, Licko V. Physiochemical
and physiological factors influencing the effectiveness of inhaled
insulin:. Buffalo Grove: Interpharm Press In:
Byron PR, Dalby R, Farr SJ, editors. Respiratory Drug Delivery 1998: 25-33
-
8
Ferrannini E, Linde B, Faber O.
Effect
of bicycle exercise on insulin absorption and subcutaneous blood
flow in the normal subject.
Clin Physiol.
1982;
2
59-70
-
9 Galloway J A, Chance R E. Approaches
to insulin analogues. Elsevier Science B.V. Amsterdam In:
Marshall SM, Home PD: The Diabetes Annual/8 1994: 277-297
-
10
Galloway J A, Spradlin C T, Nelson R L, Wentworth W M, Davidson J A, Swarner J L.
Factors influencing
the absorption, serum insulin concentration, and blood glucose responses
after injections of regular insulin and various insulin mixtures.
Diab
Care.
1981;
4
366-376
-
11
Gaensslen M.
Über
Inhalation von Insulin.
Klin Wschr.
1925;
4
71
-
12
Gerber R A, Cappelleri J C, Kourides I A, Gelfand R A, Chandler L P, Gorkin L.
Improved patient satisfaction
with inhaled insulin in subjects with type 1 diabetes mellitus:
results from a multicenter randomized controlled trial.
Diabetes.
1999;
48
A53
(Suppl 1)
-
13
Gelfand R A, Law C G, Schwartz S L, Horton M, Pun E F.
Pharmacologic
reproducibility of inhaled human insulin pre-meal dosing in patients
with type 2 diabetes mellitus (NIDDM).
Diabetes.
1998;
47
A388
(Suppl 1)
-
14
Gonda I, Schuster J A, Rubsamen R M, Lloyd P, Cipolla D, Farr S J.
Inhalation
delivery systems with compliance and disease management capabilitise.
J
Contr Release.
1998;
53
269-274
-
15
Hilsted J, Madsbad S, Hvidberg A. et al .
Intranasal insulin therapy: The clinical
realities.
Diabetologia.
1995;
38
680-684
-
16
King H, Aubert R E, Hermann W H.
Global burden
of diabetes, 1995 - 2025 - Prevalence,
numerical estimates, and projections.
Diab Care.
1998;
21
1414-1431
-
17
Kipnes M, Otulana B, Clauson P. et al .
A comparison of the pharmacodynamic effects
of inhaled insulin versus subcutaneous insulin in type 1 diabetic
patients.
Diabetes.
1999;
48
A410
(Suppl 1)
-
18
Koivisto V A, Fortney S, Hendler R, Felig P.
A rise in ambient temperature augments
insulin absorption in diabetic patients.
Metabolism.
1981;
30
402-405
-
19
Laube B L, Benedict G W, Dobs A S.
The
lung as an alternative route of delivery for insulin in controlling
postprandial glucose levels in patients with diabetes.
Chest.
1998;
114
1734-1739
-
20
Laube B L, Georgopoulos A, Adams G K.
Preliminary
study of the efficacy of insulin aerosol delivered by oral inhalation
in diabetic patients.
JAMA.
1993;
270
2106-2109
-
21
Lauritzen T, Binder C, Faber O K.
Importance
of insuline absorption, subcutaneous blood flow and residual beta-cell
function in insulin therapy.
Acta Pediatr Scand.
1980;
283
81-85
-
22
Major R H.
The
intranasal application of Insulin.
J Lab Clin Med.
1935;
21
278-280
-
23
Mc E lduff, Farr S, Ward E. et
al .
Comparison of the pharmacokinetics and pharmacodynamics
of subcutaneous and inhaled insulin Lispro in healthy fasted volunteers.
Diabetes.
1998;
47
A413
(Suppl 1)
-
24
Moses A C, Gordon G S, Carey M C. et al .
Insulin administered intranasally as an
insulin-bile salt aerosol: effectiveness and reproducibility in
normal and diabetic subjects.
Diabetes.
1983;
32
1040-1047
-
25
Patel H M, Stevenson R W, Parsons J A. et al .
Use of liposomes to aid intestinal absorption
of entrapped insulin in normal and diabetic dogs.
Biochem
Biophys Acta.
1982;
716
188-193
-
26
Pfützner A, Rave K, Heise T. et
al .
Inhaled Technosphere™/Insulin
results in low variability in metabolic action in type 2 diabetic
patients.
Exp Clin Endocrinol Diabetes.
2000;
5
S161, A113
-
27
Pontiroli A E, Alberetto M, Secchi A. et al .
Insulin given intranasally induces hypoglycaemia
in normal and diabetic subjects.
Brit Med J.
1982;
284
303-306
-
28
Rave K, Heise T, Pfützner A. et al .
Assessment
of dose-response characteristics for a new pulmonary insulin formulation
and inhaler.
Exp Clin Endocrinol Diabetes.
2000;
5
S161, A114
-
29
Saffran M, Field J B, Pena J, Jones R H, Okeeda Y.
Oral
insulin in diabetic dogs.
J Endocrinol.
1991;
131
267-278
-
30
Salzman R, Manson J E, Griffing G T. et al .
Intranasal aerosolized insulin - Mixed
meal studies and long-term use in type I Diabetes.
New
Engl J Med.
1985;
312
1078-1084
-
31
Skyler J S, Gelfand R A, Kourides I A.
A
three-month, multicenter clinical trial of therapy with inhaled
human insulin in type 1 diabetes mellitus.
Diabetologia.
1998;
41
A169
(Suppl ))
-
32
Spangler R S.
Insulin
administration via liposomes.
Diab Care.
1990;
13
911-922
-
33
Steiner S, Rave K, Heise T. et
al .
Pharmacokinetic properties and bioavailability
of inhaled dry powder Technosphere™/Insulin.
Exp
Clin Endocrinol Diabetes.
2000;
5
S161, A115
-
34
Ulrich A, Gray A, Tam A W. et al .
Insulin-like growth factor I recepror primary
structure: Comparison with insulin receptor suggests structural
determinants that define functional specifity.
EMBO J.
1986;
5
2503-2512
-
35
Ward E, Mc E lduff
A, Lee R -Y. et al .
Pharmacodynamics
of pulmonary delivered insulin in healthy fasted volunteers.
J
Aeros Med.
1997;
10
254
-
36
Weiss S R, Berger S, Cheng S L. et al .
Adjunctive therapy with inhaled human insulin
in type 2 diabetic patients failing oral agents: A multicenter phase
II trial.
Diabetes.
1999;
48
A48
(Suppl 1)
Korrespondenz
Dr. med. Igor Alexander Harsch
Medizinische Klinik I mit Poliklinik der Friedrich-Alexander-Universität
Erlangen-Nürnberg
Krankenhausstraße 12
91054 Erlangen
Phone: 09131/85 33434
Fax: 09131/85 33320
Email: Igor.harsch@med1.imed.uni-erlangen.de
